Document is current

Article History

Received: 10 June 2025

Accepted: 30 September 2025

First Online: 20 November 2025

Competing interests

: Ming-Sound Tsao: received compensation as a consultant for AbbVie, AstraZeneca, Daiichi Sankyo, and Sanofi, research grants (to institution) from Sanofi and AstraZeneca. Lynette Sholl: consultant for Genentech, AstraZeneca, Lilly; research funding from Genentech, Bristol Myers Squibb. Michelle Shiller: nothing to disclose. Peter Illei: received compensation as a consultant for AbbVie, AstraZeneca, Sanofi, and Boehringer Ingelheim and a research grant (to institution) from Bristol Myers Squibb. Ignacio I. Wistuba: nothing to disclose. Mary Beth Beasley: received compensation as a consultant and advisory board participant for AbbVie, Sanofi, Daiichi Sankyo, and AstraZeneca. Kurt A. Schalper: consultant or advisor: AbbVie Inc.; Agenus Inc.; AstraZeneca; Bristol Myers Squibb; CDR-Life Inc.; Clinica Alemana de Santiago; EMD Serono Inc.; F. Hoffmann-La Roche; Genmab A/S; Indaptus Therapeutics; Janssen Pharmaceuticals, Inc.; Merck Sharpe & Dohme; Moderna, Inc.; Molecular Templates, Inc.; OnCusp Therapeutics; Parthenon/Incendia Therapeutics; Picture Health, Repertoire Therapeutics; Sanofi; Sensei Biotherapeutics; Shattuck Labs, Inc.; and Takeda Pharmaceutical Company Limited. Funding: Akoya Biosciences; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; F. Hoffmann-La Roche; Lilly; Merck Sharpe & Dohme; Ribon Therapeutics; Surface Oncology; Takeda Pharmaceutical Company Limited; and Tesaro Inc./GSK. Archana Simmons, Peter Ansell, Sue Beruti: employees of AbbVie and may own stock. Mari Mino-Kenudson: has served as a compensated consultant for AstraZeneca, Boehringer Ingelheim, Pfizer, Repare, Sanofi, Daiichi Sankyo, Roche, and AbbVie, and received an honorarium for speaking and travel support from Sanofi and royalties from Elsevier.